tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Baughman G et al. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. 1995 Mol. Cell. Biol. pmid:7542743
Su Q et al. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. 1995 May-Jun Ren. Physiol. Biochem. pmid:7542793
Warty V et al. Tacrolimus analysis: a comparison of different methods and matrices. 1995 Ther Drug Monit pmid:7542809
Freeman DJ et al. Stability of FK 506 in whole blood samples. 1995 Ther Drug Monit pmid:7542810
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Sihra TS et al. A role for calcineurin (protein phosphatase-2B) in the regulation of glutamate release. 1995 Biochem. Biophys. Res. Commun. pmid:7542882
Dumont FJ et al. Increased LFA-1-mediated homotypic cell adhesion is associated with the G1 growth arrest induced by rapamycin in a T cell lymphoma. 1995 Exp. Cell Res. pmid:7543051
Corey HE et al. Renal allograft rejection in children and young adults: the Banff classification. 1995 Pediatr. Nephrol. pmid:7543274
Griffith JP et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. 1995 Cell pmid:7543369
Prud'homme GJ et al. Effects of cyclosporin A, rapamycin, and FK520 on peripheral T-cell deletion and anergy. 1995 Cell. Immunol. pmid:7543371
Migita K et al. FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. 1995 J. Clin. Invest. pmid:7543492
Lhoëst G et al. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects. 1995 J. Pharmacol. Exp. Ther. pmid:7543569
Textor SC et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. 1995 Kidney Int. pmid:7543625
Dollinger MM et al. Tacrolimus and cardiotoxicity in adult liver transplant recipients. 1995 Lancet pmid:7543645
Romero DF et al. Rapamycin: a bone sparing immunosuppressant? 1995 J. Bone Miner. Res. pmid:7543725
Rebollo A et al. Differential effect of rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2. 1995 Cytokine pmid:7543780
Lam E et al. Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs. 1995 Gene pmid:7543869
Minamoto A et al. Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. 1995 Jpn. J. Ophthalmol. pmid:7543958
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Ishikawa A et al. [A case of tacrolimus-induced glucose intolerance following renal allografting]. 1995 Hinyokika Kiyo pmid:7544064
Lochmüller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. 1995 Biochem. Biophys. Res. Commun. pmid:7544122
Deschler DG et al. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. 1995 Arch. Otolaryngol. Head Neck Surg. pmid:7544136
Rouvière-Fourmy N et al. 1H and 15N assignment of NMR spectrum, secondary structure and global folding of the immunophilin-like domain of the 59-kDa FK506-binding protein. 1995 Eur. J. Biochem. pmid:7544285
Sakamoto K et al. A new assay method for immunosuppressants with a tacrolimus (FK506)-like mode of action. 1995 J. Antibiot. pmid:7544337
Lee MJ et al. Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation. 1995 Immunopharmacol Immunotoxicol pmid:7544367
Sauer P et al. In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretion. 1995 J. Hepatol. pmid:7544368
Chang HY et al. Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. 1995 Nature pmid:7544441
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Llull R et al. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. 1995 Transplant. Proc. pmid:7544504
Hayashi S et al. Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation. 1995 May-Jun J. Heart Lung Transplant. pmid:7544621
Hoshino H et al. Effects of FK506 on an experimental model of colitis in rats. 1995 Aliment. Pharmacol. Ther. pmid:7544633
Firdaous I et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. 1995 Clin. Chem. pmid:7544705
Ingels SC et al. Stability of FK506 (tacrolimus) in whole-blood specimens. 1995 Clin. Chem. pmid:7544707
Takizawa H et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. 1995 Digestion pmid:7544748
Sher LS and Makowka L Immunosuppression: now we have choices. 1995 Hepatology pmid:7544759
Perrot-Applanat M et al. The 59 kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus. 1995 J. Cell. Sci. pmid:7544801
Hibi S et al. Severe rhabdomyolysis associated with tacrolimus. 1995 Lancet pmid:7544861
Kinoshita I et al. Myoblast allotransplantation in primates. 1995 Muscle Nerve pmid:7544871
Monsour HP et al. Renal insufficiency and hypertension as long-term complications in liver transplantation. 1995 Semin. Liver Dis. pmid:7544917
Varela E [Small bowel transplantation]. 1995 Acta Gastroenterol. Latinoam. pmid:7544939
Taler SJ et al. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. 1995 Am. J. Hypertens. pmid:7544983
Robertus J Structure-based drug design ten years on. 1994 Nat. Struct. Biol. pmid:7545074
Teague S Lessons from molecular matchmakers. 1995 Nat. Struct. Biol. pmid:7545076
Ito T et al. Immunosuppressive agents induce the reduction of local pancreatic blood flow. 1995 Pancreas pmid:7545292
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Han CW et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. 1995 Bone Marrow Transplant. pmid:7545487
Hattori Y and Nakanishi N Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. 1995 Cell. Immunol. pmid:7545550
Han JW et al. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. 1995 J. Biol. Chem. pmid:7545671
Ruff VA and Leach KL Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. 1995 J. Biol. Chem. pmid:7545680
Matsuo S and Okamoto K Enhancement of FK-506 activities by ganglioside (GM3) in vivo. 1995 Life Sci. pmid:7545772
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Okamoto M et al. In situ proliferating status of mononuclear cells in rat small bowel grafts. 1995 Int J Exp Pathol pmid:7547442
Pham SM et al. Cardiac transplantation at the University of Pittsburgh: 1994 update. 1994 Clin Transpl pmid:7547531
Abu-Elmagd K et al. Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. 1994 Clin Transpl pmid:7547533
Shapiro R et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. 1994 Clin Transpl pmid:7547544
Platz KP et al. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation. 1995 Clin Transplant pmid:7549052
Mueller AR et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? 1995 Clin Transplant pmid:7549057
Nagai H et al. Effect of some immunosuppressors on allergic bronchial inflammation and airway hyperresponsiveness in mice. 1995 Int. Arch. Allergy Immunol. pmid:7549508
Reisman L et al. Modulation of interleukin-1 secretion by immunosuppressive drugs, alone and in combination. 1995 Transpl. Immunol. pmid:7551978
Woo J et al. Effects of FK 506 on chimerism and the induction of donor-specific unresponsiveness following fully allogeneic bone marrow transplantation in mice. 1995 Transpl. Immunol. pmid:7551985
Kelly PA et al. Tacrolimus: a new immunosuppressive agent. 1995 Am J Health Syst Pharm pmid:7552894
MacDonald AS and Sketris IS Tacrolimus in transplantation. 1995 Am J Health Syst Pharm pmid:7552906
Holmes JA and Twentyman PR The activity of deoxyspergualin in multidrug-resistant cells. 1995 Cancer Chemother. Pharmacol. pmid:7554042
Elitsur Y et al. FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. 1995 Dig. Dis. Sci. pmid:7555446
Kobayashi I et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. 1995 Eur. J. Pediatr. pmid:7556338
Adachi M et al. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. 1995 FEBS Lett. pmid:7556630
David M et al. [Occurrence of suspicious changes in cervix cytology in women after liver transplantation]. 1995 Geburtshilfe Frauenheilkd pmid:7557217
Zhu D et al. Myristoylation of calcineurin B is not required for function or interaction with immunophilin-immunosuppressant complexes in the yeast Saccharomyces cerevisiae. 1995 J. Biol. Chem. pmid:7559604
[Experimental and clinical studies on the effectiveness of new immunosuppressive agents used in heart transplantation and transplantation-related complications]. 1995 Nihon Kyobu Geka Gakkai Zasshi pmid:7561285
Dix SP et al. Re: Severe interaction between methotrexate and a macrolide-like antibiotic. 1995 J. Natl. Cancer Inst. pmid:7563209
Hadad SJ et al. FK 506: effects on glomerular hemodynamics and on mesangial cells in culture. 1995 Kidney Int. pmid:7564092
Mazur P et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. 1995 Mol. Cell. Biol. pmid:7565718
Spencer DM et al. A general strategy for producing conditional alleles of Src-like tyrosine kinases. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7568222
Holsinger LJ et al. Signal transduction in T lymphocytes using a conditional allele of Sos. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7568223
Díaz M et al. [Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)]. 1995 Apr-Jun Rev Med Univ Navarra pmid:7569553
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Petrides AS [Do immunosuppressive agents really impair glucose tolerance in liver transplant patients?]. 1995 Z Gastroenterol pmid:7571761
Thomson AW and Bonham CA Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. 1995 Adv. Exp. Med. Biol. pmid:7572394
Paterson JM et al. Control of a novel adenylyl cyclase by calcineurin. 1995 Biochem. Biophys. Res. Commun. pmid:7575502
Cunningham EB The human erythrocyte membrane contains a novel 12-kDa inositolphosphate-binding protein that is an immunophilin. 1995 Biochem. Biophys. Res. Commun. pmid:7575593
Ellis D Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. 1995 Pediatr. Nephrol. pmid:7577418
Furuke K et al. Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control. 1995 Int. Immunol. pmid:7577807
Kawahara K et al. Effects of deoxyspergualin on bronchial anastomosis healing in canine pulmonary allografts. 1995 Jul-Aug J. Heart Lung Transplant. pmid:7578196
Mehta BA et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. 1995 Blood pmid:7579455
Hemenway C FK506 in bone marrow transplantation. 1995 Blood pmid:7579473
Yamamoto M et al. Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. 1995 Anticancer Drugs pmid:7579561
O'Gorman MA et al. Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. 1995 Clin Transplant pmid:7579739
Kanamaru A et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. 1995 Bone Marrow Transplant. pmid:7581086
Koehler MT et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:7581088
Jung-Testas I et al. Cyclosporin A promotes nuclear transfer of a cytoplasmic progesterone receptor mutant. 1995 C. R. Acad. Sci. III, Sci. Vie pmid:7583777
Kahan BD New immunosuppressive drugs--pharmacologic approaches to alter immunoregulation. 1994 Ther Immunol pmid:7584478
Tsuchida M et al. The effects of FK506 and dexamethasone on rat thymocyte differentiation. 1994 Ther Immunol pmid:7584489
Lauerma AI Immunomodulation of contact dermatitis. 1995 Curr. Probl. Dermatol. pmid:7587333
Wera S et al. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. 1995 Endocr. Res. pmid:7588431
Stoller G et al. A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. 1995 EMBO J. pmid:7588623
Farcasanu IC et al. Protein phosphatase 2B of Saccharomyces cerevisiae is required for tolerance to manganese, in blocking the entry of ions into the cells. 1995 Eur. J. Biochem. pmid:7588708